Therapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse model

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 1, 2012, Pages 191-197

  Xiao, Xinye ^a,b   He, Huan ^a   Lin, Zhirong ^a   Luo, Pingping ^a   He, Hui ^a   Zhou, Tong ^a   Zhou, Yueping ^a   Liu, Zuguo ^a  

^a XIAMEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MUCIN 1; BENZALKONIUM; EYE DROPS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; DRY EYE; GOBLET CELL; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LACRIMATION; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; BENZALKONIUM COMPOUNDS; BLOTTING, WESTERN; CORNEA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; EPIDERMAL GROWTH FACTOR; FOLLOW-UP STUDIES; GOBLET CELLS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

EID: 84857763836     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8553     Document Type: Article

References (35)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:75-92.
2. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
3. Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347-1351.
4. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096-1101.
5. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459-461.
6. Quinto GG, Campos M, Behrens A. Autologous serum for ocular surface diseases. Arq Bras Oftalmol. 2008;71:47-54.
7. Kojima T, Higuchi A, Goto E, et al. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27(suppl 1):S25-S30.
8. Leibowitz HM, Morello S Jr, Stern M, et al. Effect of topically administered epidermal growth factor on corneal wound strength. Arch Ophthalmol. 1990;108:734-737.
9. Huo Y, Qiu WY, Pan Q, et al. Reactive oxygen species (ROS) are essential mediators in epidermal growth factor (EGF)-stimulated corneal epithelial cell proliferation, adhesion, migration, and wound healing. Exp Eye Res. 2009;89:876-886.
10. Marquez EB, Ortueta DD, Royo SB, et al. Epidermal growth factor receptor in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol. 2011;30:7-14.
11. Zhang Y, Liou GI, Gulati AK, et al. Expression of phosphatidylinositol 3-kinase during EGF-stimulated wound repair in rabbit corneal epithelium. Invest Ophthalmol Vis Sci. 1999;40:2819-2826.
12. Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs. 2007;30:S10-S16.
13. Xiong C, Chen D, Liu J, et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2008;49:1850-1856.
14. Lin Z, Liu X, Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis. 2011; 17:257-264.
15. Pauly A, Brignole-Baudouin F, Labbe A, et al. New tools for the evaluation of toxic ocular surface changes in the rat. Invest Ophthalmol Vis Sci. 2007;48:5473-5483.
16. Laria C, Alio JL, Ruiz-Moreno JM. Combined non-steroidal therapy in experimental corneal injury. Ophthalmic Res. 1997;29:145-153.
17. Sakamoto R, Bennett ES, Henry VA, et al. The phenol red thread tear test: a cross-cultural study. Invest Ophthalmol Vis Sci. 1993; 34:3510-3514.
18. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
19. Chen W, Zhang X, Zhang J, et al. A murine model of dry eye induced by an intelligently controlled environmental system. Invest Ophthalmol Vis Sci. 2008;49:1386-1391.
20. Schrader S, Mircheff AK, Geerling G. Animal models of dry eye. Dev Ophthalmol. 2008;41:298-312.
21. Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312-334.
22. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol. 2009;218:460-466.
23. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res. 2008;314:3093-3106.
24. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J Ophthalmol. 1975;59:667-669.
25. Lee JS, Liu JJ, Hong JW, et al. Differential expression analysis by gene array of cell cycle modulators in human corneal epithelial cells stimulated with epidermal growth factor (EGF), hepatocyte growth factor (HGF), or keratinocyte growth factor (KGF). Curr Eye Res. 2001;23:69-76.
26. Yanai R, Yamada N, Kugimiya N, et al. Mitogenic and antiapoptotic effects of various growth factors on human corneal fibroblasts. Invest Ophthalmol Vis Sci. 2002;43:2122-2126.
27. Nakamura M, Nishida T. Potentiation by cyclic AMP of the stimulatory effect of epidermal growth factor on corneal epithelial migration. Cornea. 2003;22:355-358.
28. Song QH, Gong H, Trinkaus-Randall V. Role of epidermal growth factor and epidermal growth factor receptor on hemidesmosome complex formation and integrin subunit beta4. Cell Tissue Res. 2003;312:203-220.
29. Pflugfelder SC, De Paiva CS, Villarreal AL, et al. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27:64-69.
30. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
31. Horikawa Y, Shatos MA, Hodges RR, et al. Activation of mitogenactivated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2003;44:2535-2544.
32. Kinoshita S, Kiorpes TC, Friend J, et al. Goblet cell density in ocular surface disease. A better indicator than tear mucin. Arch Ophthalmol. 1983;101:1284-1287.
33. Argueso P, Balaram M, Balaram M, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci. 2002;43:1004-1011.
34. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res. 2010;90:655-663.
35. Jones DT, Monroy D, Ji Z, et al. Alterations of ocular surface gene expression in Sjogren's syndrome. Adv Exp Med Biol. 1998;438: 533-536.